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Summary Although patients with superficial bladder cancer (Ta, TI) have a generally good prognosis, those
patients who develop muscle-invasive tumours or metastatic disease at recurrence do poorly clinically. In the
current study 69 patients undergoing complete uansurethral resection for superficial transitonal cell cancer of
the bladder were investigated for different clinical and biological characteristics as possible prognostic factors:
age, sex, performance of instillation therapy and immunohistochemical determination of mutational inactiva-
tion of p53 tumour-suppressor gene (monoclonal antibody PAb 1801) as weUl as immunohistochemical
determination of the proliferation rate by staining for PCNA (proliferating ceUl nuclear antigen) (monoclonal
antibody PC 10). After a median foHow-up of45.8 months, 12 of 14 patients (85.7%) with more than 20% of
cells positive for p53 had disease progression with muscle-invasive growth compared with only one of 55
patients (1.8%) negative for p53 (P <0.01, x2 test). During univariate analysis histological grade (G, vs G2)
(P = 0.0373), positivity for PCNA (>60% of ceUls) (P =0.0033) and positivity for p53 (P <0.001) were
significant prognostic factors for disease progression (log-rank test), while during multivariate analysis only
positivity for p53 was a significant predictor for relapse of bladder cancer (P = 0.0029) (multivariate Cox
regression analysis). The immunohistochemical detection of mutations of the p53 gene has been demonstrated
to be a reliable, easily performed and thereby widely available technique for the investigation of fresh-frozen
or paraffin-embedded tumour specimens. The results demonstrate the important role of the p53 tumour-
suppressor gene protein in the development and for the progression of bladder cancer. If the high prognostic
value of p53 mutations in superficial bladder cancer is confirmed in larger prospective trials, more aggressive
therapeutic strategies could be discussed for patients with p53 mutations in their tumour specimens.
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Approximately 80% of patients with papillary transitional
cell carcinoma of the bladder will initially be diagnosed with
superficial disease. Following transurethral resection 70-80%
of these patients will develop disease recurrence within 6-12
months, and in 20% of them the tumour at relapse will be of
a higher pathological grade and at a more advanced tumour
stage. Therefore, about 10-20% of patients initially diag-
nosed with superficial bladder cancer will subsequently
develop muscle-invasive or metastatic disease. In comparison
with patients with superficial bladder cancer, the prognosis of
patients with muscle-invasive tumours or metastatic disease is
extremely poor (Pocock et al., 1982; Torti and Lum, 1987).
This has resulted in attempts to identify prognostic factors in
patients with superficial bladder cancer in order to distin-
guish patients with a highly aggressive tumour type from
those with a much more indolent course of the disease
(Pocock et al., 1982).
The p53 gene has been identified as a tumour-suppressor
gene located on chromosome 17p. The product of the gene is
a nuclear phosphoprotein involved in cell cycle regulation
arresting cells in the G, phase (Lane and Crawford, 1979;
Jenkins et al., 1984; Finlay et al., 1989; Bischoff et al., 1990).
Mutations of the p53 tumour-suppressor gene, which often
result in accumulation of the altered gene product, have been
identified in a variety of human malignancies, such as colo-
rectal carcinoma, breast cancer and carcinoma of the pros-
tate (Starzynska et al., 1992; Thor et al., 1992; Visakorpi et
al., 1992). Detection of this genetic event is therefore possible
by the use of immunohistochemical methods (Kuczyk et al..
1993; Bokemeyer et al., 1994).
For patients with superficial transitonal cell carcinoma of
the bladder a correlation between a strong immunohisto-
chemical staining reaction for p53 and invasive behaviour of
the tumour with poor clinical outcome has been proposed
(Sarkis et al., 1993a).
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In 69 patients with superficial blader cancer (T1) undergo-
ing complete transurethral tumour resection, we investigated
the overexpression of the p53 protein by immunohistochemi-
stry using the monoclonal antibody PAb 1801. Detection of
the p53 protein was correlated with further clinically impor-
tant variables: sex, age, former instillation therapy and finally
the clinical course of the patients. One additional aim of the
study was to demonstrate the usefulness of immunohisto-
chemistry alone without additional molecular genetic investi-
gation as widely applicable method for the study of prognostic
markers in superficial bladder cancer.
Patets and methods
Patients
The medical charts of 69 patients (59 males and ten females)
with superficial bladder cancer treated by complete tran-
surethral resection (TUR) of the tumours were reviewed. The
median age of the patients was 72.3 years (range 50-92
years). All tumour specimens were classified as Tl and
graded according to the TNM system. The median follow-up
after TUR was 45.8 months (range 12-104 months). All
tumours were pathologically graded as grade 1 or grade 2
and patients with, in addition, carcinoma in situ within the
urothelium adjacent to the tumours were not included in the
study.
Patients routinely underwent a mapping biopsy 6 weeks
after the first TUR. If no recurrence or residual tumour was
diagnosed the patients were followed by cystoscopy every 3
months during the first year and every 3-6 months during
the years thereafter. Patients developing a muscle-invasive
tumour underwent radical cystectomy.
Immunohistochemistry
For the immunohistochemical detection of the p53 onco-
protein, tissue sections from 69 superficial (TI) formalin-fixed
and paraffin-embedded bladder tumours were stained for thep53 Imnwnostaining as a prognstic factorfor rlapse o superflcia bbdde cancer
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p53 protein. p53 immunoreactivity was also studied in seven
biopsy specimens from normal bladder epithelium in non-
tumour-bearing patients.
Following deparaffinisation the tumour specimens were cut
serially at 8ym thickness and stained by an identical
immunohistochemical procedure. as described below.
Positive controls were represented by tumour specimens
known to contain a mutational inactivation of the p53
tumour-suppressor gene as detected by DNA sequence
analysis of the p53 gene. As an internal negative control for
the staining procedure. each tumour in the study was
incubated with non-immune mouse IgG instead of the
primary antibody. followed by the identical procedure for the
application of the secondary antibodies. Seven biopsies from
normal bladder epithelium and the normal mesenchymal cells
within the tissue sections of the resected tumours served as
biological negative controls.
Immunohistochemistry for p53 protein was performed as
follows. Tumour-bearing slides were first incubated with nor-
mal human serum in a dilution of 1: 100 in TIns-buffered
saline (TBS; 0.05 M. pH 7.6) to prevent non-specific binding
of the first antibody. Then the specific primary antibody for
the detection of p53 (PAb 1801 IDianova Hamburg, Ger-
many) (Banks et al.. 1986) was added. This mouse mono-
clonal antibody recognises a denaturation-resistant epitope in
both mutant and wild-type p53 proteins and enables the
detection of altered p53 proteins within the cell nucleus
because of their prolonged half-life caused by conformational
changes as a result of the genetic mutation (Finlay et al.,
1988). The PAb 1801 antibodies were applied in a dilution of
1:50 in TBS at room temperature for 1 h in a moist chamber.
After rinsing with TBS 0.I% Tween 20 for 10 min, the
sections were incubated with a second monoclonal antibody
of rabbit anti-mouse specificity (Z 259, Dako. Hamburg.
Germany). This antibody was applied in a mixture of human
serum and TBS (1:25) for 30 mn diluted 1:25. After a third
rinsing with Tween 20 TBS the alkaline phosphatase-anti-
alkaline phosphatase (APAAP) complex (Dako) was added
in a dilution of 1:50 in TBS for 30 min. After a final rinsing
with Tween 20 TBS the red reaction product was obtained
following the typical chemical reaction procedure. Finally the
slides were counterstained by haematoxylin.
For the immunohistochemical detection of proliferating
cells. monoclonal antibodies for 'proliferating cell nuclear
antigen' (PCNA) (PC 10 diluted 1:100 in TBS) (Dako)
(Waasem and Lane. 1990) were used as primary antibodies.
The reaction was made visible by the same method for all
types of primary antibodies used.
Classification ofimmunohistochemistrv and additionally
determined variables
Depending on the percentage of nuclei exhibiting a positive
immunohistochemical staining reaction for the p53 protein.
the tumours were classified into six groups: (0) tumours with
a negative staining reaction: (1) <20% positivity: (2)
20-40%0 (3) 40-60%; (4) 60-80%: (5) 80-100%. For the
statistical analysis the p53 reaction was graded into two
groups: group A. <20% positivity; group B, >20% posi-
tivity (Table I). The immunohistochemical reaction for the
p53 protein was considered to be positive only when the
nucleus was stained. For analytical purposes, the highest
category obtained in each patient was considered. Five
separate slides per patient were reviewed and classified by
two independent investigators.
For the detection of proliferative activity the tumours were
immunohistochemically stained for the proliferation marker
PCNA. The immunohistochemical reaction for the prolifera-
tion marker PCNA was classified in six groups similarly
defined to those described above for p53 staining. As addi-
tional factors histological grade, the age and sex of patients
and performance or absence of instillation therapy were con-
sidered.
Table I Charactenstics of all patients in whom more than 20o of
tumour cells stained positively for the p53 protein (group B)
Sex and age
(Yearsv TTP TP PCNA p53
Male (50) 2 Yes 4 2
Male (80) 11 Yes 5 4
Male (69) 47 No 3 3
Male (84) 23 Yes 3 3
Male (62) 10 Yes 4 2
Male (79) 17 Yes 4 3
Male (62) 32 Yes 4 4
Male (86) 8 Yes 4 4
Female (62) 10 Yes 3 3
Male (89) 13 Yes 5 4
Male (74) 16 Yes 4 3
Male (76) 21 Yes 4 3
Male (56) 34 Yes 3 3
Male (62) 34 No 3 4
NP. no disease progression: TP. tumour progression: TTP. time to
progression in months. Immunohistochemical classification for p53
and PCNA: (2. 20-40% positive: 3. 40-60%; 4. 60-80°o: 5.
80-100%)-
Statistical calculation
Univariate analysis using the log-rank test was employed to
determine the prognostic significance value for disease pro-
gression of each factor alone. Chi-squared tests with Yates'
corrections were used to calculate the influence of the above-
mentioned variables on the immunohistochemical reactivity
for the p53 protein. Progression-free intervals were defined as
the time between surgical intervention (TUR) and the de-
velopment of invasive tumour growth or end of the follow-up
period. Progression-free survival was calculated according to
the Kaplan-Meier method from the start of the treatment.
Finally. multivariate Cox regression analysis was used in
order to determine whether any of the factors tested - age,
sex. instillation therapy. histological grade or PCNA and p53
positivity - could be identified as an independent prognostic
factor for disease progression.
Results
Depending on the number of cells stained positively for the
p53 protein, two groups of tumours were identified. In 39 of
the 69 tumour specimens (56.5%) less than 20% of cells
exhibited a positive staining reaction for the p53 protein.
Additionally. 16 patients (23%) showed a completely nega-
tive reaction for p53. These 55 patients were grouped to-
gether as group A. In 14 tumours (20%) the number of cells
stained positively for the p53 protein was greater than 20%
(two patients. 20-40% positive: seven patients. 40-60%
positive; five patients. 60-80% positive) (group B). In most
biopsies with <20% p53 staining, the positive cells were
arranged in clusters, All seven cases of normal bladder tissue
were negative for the p53 protein. Moreover, the normal
mesenchymal cells in all 69 bladder tumours did not exhibit
any nuclear reactivity.
With a median follow-up of 45.8 months. 1 of 55 patients
(1.8%) from group A (<20% p53 positivity) developed
disease progression, in contrast to 12 of 14 patients from
group B (> 20% p53 positivity). The median time to tumour
progression for group B was 16.4 months (Table I)
(P <0.001. log-rank test).
Kaplan-Meier curves for time to disease progression for
patients of groups A and B are shown in Figure 1.
In tumours from group A. positive staining reactions for
PCNA were observed as follows: 12 patients, 0-20%
positive: 14 patients. 20-40% positive; 13 patients. 40-60%
positive: 11 patients, 60-80% positive; five patients,
80- 100% positive. In 9 of 14 tumours (64.3%) from group B
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Fugwe 1 Progression-free survival, caulated according to the
Kaplan-Meier method. Cla at into group A (<20'!.) and
group B (>20% of cels staming postively for the p53 protein).
Group B patents had a highly significant risk of proson
(P<0.001, log-rank test).
The patients in groups A and B were similar with respect
to their clinical charactefistics. The median age in groups A
and B was 71.4 and 71.1 years respectively. Tbirteen patients
from group A (23.6%) received instillation therapy in com-
parison with two of the patients from group B (14.3%). The
characteristics of all patients with p53 positivity are given in
Table I.
Statistical analysis
Univariate analysis by log-rankc tests demonstrated that
tumour progression was independent of age (P = 0.9504), sex
(P = 0.9754) and performance of former instillation therapy
(P = 0.4968). A significant correlation was found with
tumour grade (P = 0.0373) and proliferative activity as
indicated by PCNA positivity (P = 0.0033) and p53 positivity
(P <0.001).
Multivariate analysis revealed p53 overexpression
(P = 0.0029) as the most important single prognostic factor
for disease progression wh comp with grade
(P = 0.8991), age (P = 0.8863), sex (P = 0.6051) and pro-
liferative activity (P = 0.75).
Chi-squared tests were performed to compare p53 over-
expression with instillation therapy (P = 0.4487), which was
found to be not significantly correlated to p53 positivity.
However, p53 expression was statstically significantly corre-
lated with tumour grade (P = 0.024) and a high proliferative
activity (>60% of cells stained positively for PCNA)
(P <0.05).
There have been many attempts to find prognostic para-
meters for patients with superficial bladder cancer (Ta, TI)
that would identify the subgroup with highly aggressive car-
cinoma and a high likelihood of disea rurce with
muscle-invasive growth or metastatic spread. Aggressive
therapeutic approaches such as early radical cystectomy fol-
lowing transurethral resection of the primary tumour or at
least more active instillation therapy could be options for
these poor prognosis patients.
Candidate parameters include carcinoembryonal antigen
(CEA) urine levels or immunohistochemical staining for
Tbomsen-Friedenreich antigen or the antigens of the ABO
blood group system on the surface of tumour cells (Jakse et
al., 1983; Summers et al., 1983). DNA ploidy of tumour cells
and the percentage of tumour cells in S-phase have been
correlated with the prognosis and the clinical course of the
disease (Hofstidter et al., 1986). The proliferation rate as
determined by the percentage of cells in S-phase seems to
possess a higher prognostic value for disease progression
than tumour ploidy (Tubiana and Courdi 1989). The im-
munohistochemical assessment of proliferation rate by
monoclonal antibodies for PCNA and Ki-67, a nuclear anti-
gen present during active cell cycling and mitosis, has also
p53 s asa pposcfar cbr reapeedsapulira lb.r c,
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been correlated with clinical course (Gerdes, 1990). Addi-
tionally, immunohistochemical positivity for PCNA has been
correlated with the grade and stage of bladder tumours
(Lipponen and Eskelinen, 1992a). In a multivariate analysis
in patients with superficial, muscle-invasive and metastatic
bladder cancer, the percentage of PCNA-positive nuclei was
an independent prognostic factor for survival (P = 0.046)
(Lipponen and Eskelinen, 1992b).
The rapid development of new techniques in moleular
genetics of tumour cells has expanded the search for useful
prognostic factors in bladder cancer. Malignant transforma-
tion involves the activation of oncogenes and the mutational
inactivation of tumour-suppressor genes (Harris and Holl-
stein, 1993). Recent cytogenetic studies have demonstrated
non-random changes in chromosomes 1, 5, 7, 9, 11 and 17 in
superficial and locally advanced bladder cancer (Borland et
al., 1992). Altered expression of c-erbB-2 as well as muta-
tional inactivation of the tumour-suppressor gene p53 and
the retinoblastoma gene (Rb) have been described (Wright et
al., 1991). In a cohort of 43 patients with locally advanced
bladder cancer altered Rb expression was identified as an
independent prognostic factor for tumour-free survival rate
(Logothetis et al., 1992). The mutational inactivation of the
p53 gene was the first genetic alteration demonstrated to
occur in primary invasive bladder tumours (Sidransky et al.,
1991).
Mutation of the p53 gene usually leads to a protein with
an altered configuration, often assocated with prolonged
half-life and higher intracellular levels compared with the
wild-type protein, thereby allowing its immunohistochemical
detection (Finlay et al., 1988). The speificity of the immuno-
histochemical staining reaction for p53 protein was confirmed
by comparison of the results with the detection of mutational
inactivation of the p53 gene by DNA sequence analysis
(Dalbagni et al., 1993). Accumulation and immunohisto-
chemical detection of the mutated p53 protein has been
described for carcinoma of the breast (Horak et al., 1991;
Harris, 1992; Thor et al., 1992), colorectal carcinoma (Hamil-
ton, 1992; Starzynska et al., 1992) and primary lung cancer
(Gazdar, 1992; Quinlan et al., 1992) and has been correlated
with a poor clinical outcome.
Sarkis et al. (1993a) investigated 43 superficially growing
bladder tumours (TI) with a median follow-up of 119
months for overexpression of the p53 protein using an
immunohistochemicl method. In 30 patients the bladder
tumour was treated by TUR alone without adjuvant intra-
vesical instillation therapy. A positive staining reaction in less
than 20% of tumour cells was found in 18 tumours (42%),
and in 25 patients more than 20% of tumour cells were
stained positively for the p53 protein (58%). These patients
had a signifcntly shorter progression-free interval
(P = 0.01). While only three of 18 (17%) patients with
<20% p53 positivity showed disease progression, 19 of 25
(76%) patients with p53 expression in >20% of tumour cells
suffered from tumour progression.
The study reported here with a median follow-up of 45.8
months found a lower percentage ofp53 positivity in patients
with superficial bladder cancer. In 55 of69 tumour specimens
kss than 20% of tumour cells stained positively for the p53
protein (group A) (79.7%) and only in 14 bladder tumours
more than 20% of cells exhibited a positive nuclear staining
reaction (Group B) (20.3%). One patient from group A
(1.8%) but 12 patients from group B (85.7%) had disease
progression. This difference between both groups was statis-
ically significant (P <0.001).
Following univariate and multivariate statistical analysis,
Sarkis et al. (1993a) have described p53 overexpression as a
prognostic factor independent of age, sex, tumour grade and
vascular invasion. In our study univariate analysis revealed,
in addition to p53 positivity, an influence of histological
grade (P = 0.0373) and proliferation rate detected by im-
munohistochemical staning for PCNA (P =0.0033) on
diseae progression. However, the multivariate analysis
demonstrated p53 to be the most important and independent
prognostic factor for disease progression (P =0.0029).p53 Imn as a po_gnsic fader for relapse of superfial badder cancr
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Table II Prognostic factors for disease progression in 41 patients
with superficial bladder cancer
Prognostic Prognostic
Factor value value
investigated (univariate} (multivariate) (P}
Age No (0.9504) No (0.8863)
Sex No (0.9754) No (0.6051)
p53 positivity Yes (0.001) Yes (0.0029)
Tumour grade Yes (0.0373) No (0.8991)
PCNA positivity Yes (0.0033) No (0.750)
Instillation therapy No (0.4968) No (0.750)
Lipponen and Eskelinen (1992h) identified the proliferation
rate (as determined by staining of PCNA) as a prognostic
factor for bladder cancer. However, when compared with p53
immunohistochemistry in our patients this approach was of
prognostic value only in tumours in which more than 60% of
cells stained positively for PCNA. During the multivanrate
analysis (Table II) iimmunohistochemistry for the p53 onco-
protein was clearly more important than PCNA detection.
Both the loss of a significant prognostic value of PCNA
during multivariate analysis and the high cut-off level of 60%
of positive cells during univariate analysis indicate the low
sensitivity of this prognostic factor compared with staining
for p53.
Unfortunately. p53 overexpression in the current study
could not be correlated to smoking history owing to absence
of the appropriate data in these patients. Smoking has been
demonstrated to increase the frequency of p53 mutations for
patients with bladder cancer (Spruck et al.. 1993) and may
therefore contribute to the prognosis either as part of the
change of p53 or independently.
In our study the value of instillation therapy could not be
adequately assessed since only a small number of patients had
received this treatment modality. Further studies are neces-
sary to clarify the effect of different agents (BCG,mitomycin)
and therapeutic regimens for intravesical instillation on the
clinical course of bladder tumours possessing a mutational
inactivation of the p53 protein. If our results can be con-
firmed in larger prospective trials, they may be an argument
for more aggressive strategies in patients identified by the p53
inactivation in order to prevent tumour recurrence following
TUR. If, for example, instillation therapy has no effect on
the clinical course of tumours presenting with an inactivation
of the p53 tumour-suppressor gene. perhaps because of the
clonal but multifocal origin of bladder cancer (Sidransky et
al., 1993), radical cystectomy might be the only curative
treatment option.
Interestingly, in contrast to the findings in superficially
growing bladder tumours (TI), the immunohistochemical de-
tection of the p53 oncoprotein has no prognostic value in
muscle-invasive bladder cancer (Sarkis et al.. 1993b). This
may indicate that inactivation of p53 may represent a rather
early event in the development of bladder cancer.
The immunohistochemical approach for p53 is easy, widely
available and accurate as compared with DNA sequence
analysis (Dalbagni et al., 1993), and further prospective
studies should be encouraged.
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